ArticleFrontiers in immunology2026
HERV-W association with serum biomarkers NfL and GFAP in multiple sclerosis.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Serum biomarkers of multiple sclerosis (MS), such as glial fibrillary acidic protein (sGFAP) and neurofilament light chain (sNfL), are established indicators of disease progression and disability. Human endogenous retrovirus of the W family (HERV-W) is repeatedly associated with MS neuroinflammation, but its relationship with neural injury biomarkers is unclear. Methods: We measured anti-pHERV-W, -syncytin-1 IgG and their Ratio (HERV-W) in 83 RR-MS patients and 112 healthy controls (HC). Age and sex-adjusted sNfL/sGFAP Z-scores were derived from HC-calibrated GAMLSS models. HERV-W humoral responses were correlated with MS severity score (MSSS), cytokines (Olink™), and clinical phases (acute MS [AMS], stable MS [SMS]) Results: HERV-W showed no difference between MS patients and HC, consistent with stable low-EDSS RR-MS predominance. HERV-W ratio correlated positively with Z-sNfL (ρ=0.67, p=0.012), Z-sGFAP (ρ=0.54, p=0.048), MSSS, and proinflammatory cytokines (IL-6, IL-1β and CXCL-9/10) specifically in AMS and SMS-EDSS>4 subgroups. AMS patients with elevated sNfL (>10 pg/ml; Z-score >1.5) exhibited markedly higher HERV-W than those with lower sNfl values. Discriminant models combining HERV-W, sNfL, and sGFAP achieved 82% of accuracy for MS-EDSS>4 classification; excluding HERV-W reduced the correct MS-EDSS>4 classification by 9.1%. Conclusions: HERV-W humoral activity shows state-specific associations with sNfL and sGFAP and proinflammatory status in acute and high-disability MS phases. These findings support integrating HERV-W humoral response into dynamic biomarker panels to better stratify patients by inflammatory burden and disability trajectory, positioning it as a cofactor linking immune dysregulation to neurodegeneration rather than a singular MS marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.